- NASDAQ:VXRT gains 8.66% on Wednesday, as the micro-cap biotech industry rises.
- Operation Warp Speed funding to Johnson and Johnson gives investors hope of further payouts.
- Vaxart has a substantial war-chest to conduct a COVID-19 vaccine trial.
NASDAQ:VXRT has added to its recent surge, gaining 8.66% on Wednesday and closing the trading session at $9.66. The share price peaked after an early morning bump up to $10.99, but Vaxart spent the remainder of the day steadily declining. As with many of their rivals in the race to find a COVID-19 vaccine, Vaxart has seen its price increase by well over 2,500% so far this year, – pushing the firm’s market cap to over $1 billion. With the firm’s quarterly earnings call scheduled for next week – investors hope to hear news on the success of their vaccine in clinical development.
Update 2: VXRT shares are soaring on Friday, trading around $9.30 after hitting a daily high of $10.20. Earnings are keeping shares bid while worries about competitors' vaccines may also be in play, especially those with links to China, as Sino-American tensions are deteriorating See Reports US to sanction Hong Kong leader Carrie Lam.
Update: Vaxart is set to kick off Friday's trading session with a substantial double-digit rebound, recapturing the $10 level. The veteran company sai it had $140 million in cash at the end of July and that is it is preparing to enter a Phase 1 clinical trial with its coronavirus vaccine candidate. The upbeat news is inspiring investors, despite fierce competition, from firms such as Novavax. See: NVAX, which has three reasons to rise.
The big news of the day in the coronavirus news space has been that Johnson and Johnson (NYSE:JNJ) has agreed to provide 100 million doses of their coronavirus vaccine to Americans by 2021. The deal with the federal government is estimated to be valued at $1 billion. With the global demand for a COVID-19 vaccine at an all-time high, investors are optimistic that other companies would also be receiving government funding for their vaccine candidates. While Vaxart has five versions of its oral vaccine still in clinical trials, the firm’s candidate was selected as one of the vaccines that may be provided to Americans in 2021. Adding Vaxart’s continued involvement with Johnson and Johnson on an influenza vaccine – it is becoming clear why investors are excited about this relationship.
Vaxart Stock Forecast
As its earnings call approaches, Vaxart investors will want to know about the prospects of its oral vaccine – and how close the company is to potential distribution. Nevertheless, investors would be wise to temper their expectations of the company, as most of the Operation Warp Speed funding could be given to big-name companies like Johnson and Johnson or Glaxosmithkline (NYSE:GSK) and Pfizer (NYSE:PFE) – the latter also agreed to a deal to provide vaccines to Canada.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD trades weak below 1.0800 amid Good Friday lull, ahead of US PCE
EUR/USD remains depressed below 1.0800 after soft French inflation data, amid minimal volatility and thin liquidity on Good Friday. The pair keenly awaits the US PCE inflation data and Fed Chair Powell's speech for fresh hints on next week's price action.
GBP/USD holds steady above 1.2600 as markets stay calm on Good Friday
GBP/USD trades sideways above 1.2600 amid a typical Good Friday trading lull. A broadly firmer US Dollar could keep any upside attempts limited in the pair ahead of the US PCE inflation data and Fed Chair Powell's appearance.
Gold reaches to all-time highs near $2,230, US PCE eyed
Gold price appreciates to all-time highs near $2,230 per troy ounce, attempting to continue its winning streak for the fifth successive session on Friday. However, trading volumes are light as market participants are likely observing Good Friday.
Jito price could hit $6 as JTO coils up inside this bullish pattern
Jito (JTO) price has been on an uptrend since forming a local bottom in early January. Since then, JTO has revisited the key swing point formed in early December, suggesting the bulls’ intention to move higher.
Key events in developed markets next week
Next week, the main focus will be inflation and the labour market in the Eurozone. We expect services inflation to be impacted by the easter effect, while the unemployment rate to be unchanged.